The gist

Creates a $120 million national center to boost US biopharmaceutical manufacturing, train biotech workers, and reduce reliance on foreign drug supply chains.

Who wins, who loses

• Wins: US drug manufacturers, universities, biotech students seeking training, communities near biotech industrial clusters.
• Loses: foreign pharmaceutical suppliers; taxpayers fund $120M with no guaranteed return.

What it does

• Authorizes $120 million for fiscal year 2026 through the National Institute of Standards and Technology (NIST).
• NIST must solicit applications within 180 days and pick one winner competitively.
• Eligible applicants: universities, public-private partnerships, or consortia (no federal agencies).
• Requires progress reports to Congress at 1 year, after launch, and 5 years in.

Why should I care?

Supporters say US-made medicines protect national security and create high-skill jobs teens could train for. Critics argue picking one center wastes money better spent on broader research grants. An alternative debated: fund multiple smaller regional hubs instead of one flagship. Where do you land? Vote below and use "Tell Your Rep" to make sure your voice reaches Congress.